Dallas, TX (PRWEB) November 04, 2014
Ovarian Cancer – Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects.
Ovarian cancer occurs more frequently in women who ovulate more, thus those who never had children are at increased risk. Other risk factors include hormone therapy after menopause, fertility medication and obesity. Factors that decrease the risk include hormonal birth control, tubal ligation, and breast feeding. About 10% of cases run in families and those with the gene mutations BRCA1 or BRCA2 have an approximately 50% risk of the disease. The most common type, making up more than 95% of cases, are ovarian carcinomas. They include five main subtypes of which high-grade serous is most common. These tumors are believed to usually start from the cells covering the ovaries, though some may form from the fallopian tubes. Less common types include germ cell tumors and sex cord stromal tumors. The diagnosis is confirmed by examination of a biopsy usually removed during surgery. Complete report available at http://www.rnrmarketresearch.com/ovarian-cancer-pipeline-review-h2-2014-market-report.html.
Ovarian Cancer - Companies Involved in Therapeutics Development:
3-V Biosciences, Inc., A. Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., AbGenomics International, Inc., Acceleron Pharma, Inc., Adocia, Aduro BioTech, Inc., Advanced Accelerator Applications SA, Advantagene, Inc., Advaxis, Inc., Advenchen Laboratories, LLC, Aeterna Zentaris Inc., Alethia Biotherapeutics Inc., Almac Discovery Ltd., Ambrx, Inc., Amgen Inc., Amorfix Life Sciences Ltd., Angstrom Pharmaceuticals, Inc., AntiCancer, Inc., Aphios Corporation Aposense Ltd., Aprea AB, arGEN-X BV, Armour Therapeutics Inc., Arrien Pharmaceuticals, LLC, Ascenta Therapeutics, Inc., Ascentage Pharma Group Corporation, Ltd., Astellas Pharma Inc., AstraZeneca PLC, Atara Biotherapeutics, Inc., AVAX Technologies, Inc., Avipep Pty Ltd, Azaya Therapeutics Incorporated, Basilea Pharmaceutica AG, Bavarian Nordic A/S, BioCancell Therapeutics, Inc., BioMarin Pharmaceutical Inc., BioMoti Limited, Bionomics Limited, Bioo Therapeutics, BiOrion Technologies B.V., Biscayne Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Bolder Biotechnology, Inc., Boston Biomedical, Inc., Bristol-Myers Squibb Company, CanBas Co., Ltd., CASI Pharmaceuticals Inc., Cavion LLC, Celgene Corporation, Celldex Therapeutics, Inc., Ceronco Biosciences, Cerulean Pharma, Inc., Chikujee Therapeutics, Chipscreen Biosciences Ltd, Cold Genesys, Inc., Coronado Biosciences, Inc., Critical Outcome Technologies Inc., CritiTech, Inc., CTI BioPharma Corp., Curis, Inc., etc. Order a Purchase copy at http://www.rnrmarketresearch.com/contacts/purchase?rname=235878.
Colon Cancer – Pipeline Review, H2 2014
“Colon Cancer – Pipeline Review, H2 2014” report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects.
Colorectal cancer (colon cancer) is the development of cancer in the colon or rectum (parts of the large intestine). It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and feeling tired all the time. Complete report available at http://www.rnrmarketresearch.com/colon-cancer-pipeline-review-h2-2014-market-report.html.
Colon Cancer - Companies Involved in Therapeutics Development:
Advenchen Laboratories, LLC, Alethia Biotherapeutics Inc., AlphaVax, Inc., Ambrx, Inc., Anavex Life Sciences Corp., Aphios Corporation, Apogenix GmbH, Aptose Biosciences Inc., AstraZeneca PLC, Aurigene Discovery Technologies Limited, Bio-Path Holdings, Inc., Biokine Therapeutics Ltd., Bionomics Limited, Cellceutix Corporation, Cold Genesys, Inc., Critical Outcome Technologies Inc., CureFAKtor Pharmaceuticals. LLC, CytomX Therapeutics, Inc., CZ BioMed Corp, Daiichi Sankyo Company, Limited, Deciphera Pharmaceuticals, LLC, DEKK-TEC, Inc., Dendreon Corporation, Digna Biotech, S.L., EntreChem, S.L., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, GlycaNova Norway AS, Green Cross Corporation, Hanmi Pharmaceuticals, Co. Ltd., Histogen, Inc., Igenica Biotherapeutics, Inc., ImmunoCellular Therapeutics, Ltd., Immunomedics, Inc., Ironwood Pharmaceuticals, Inc., ISA Pharmaceuticals B.V., Jasco Pharmaceuticals, LLC., etc. Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235897.
Browse more reports on cancer therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics.
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.